What Dasiglucagon is
Dasiglucagon is a glucagon analog used in approved rescue contexts and helps show how peptide metabolic signaling becomes real medicine.
Dasiglucagon is grouped under Approved / Clinical / Fat Loss + GLP-1s on PeptideFactCheck because it is clinically important and also helps explain why glucagon signaling keeps coming up in next-generation metabolic-drug design.
The useful starting point is to separate the molecule itself from the internet story around it. It is clinically important and also helps explain why glucagon signaling keeps coming up in next-generation metabolic-drug design.
Why people keep looking it up
It is clinically important and also helps explain why glucagon signaling keeps coming up in next-generation metabolic-drug design.
Dasiglucagon is a glucagon analog used in approved rescue contexts and helps show how peptide metabolic signaling becomes real medicine.
Dasiglucagon tends to stay in the conversation because it touches a familiar public theme: glucagon receptor, emergency glucose rescue, and metabolic medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide analog with regulated, indication-specific human evidence.
Human clinical trials and official labeling support specific approved use.
Mechanism follows glucagon receptor biology and hepatic glucose mobilization.
Why this page carries the current tier: Approved peptide analog with regulated, indication-specific human evidence.
The current seed trail for Dasiglucagon is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a real emergency medicine context, not a generic metabolism-optimization product.
FDA-approved dasiglucagon products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Dasiglucagon. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Dasiglucagon is CID 126961379. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 126961379
- Formula
- C152H222N38O50
- Molecular weight
- 3381.6
- InChIKey
- RZRMFQMNPDPAIX-AJTOSFMRSA-N
Matched synonyms include Dasiglucagon, 1544300-84-6, AD4J2O47FQ, ZP-GA-1, DTXSID501336774, ZP4207, ZP-4207, His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Dasiglucagon returns 21 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Dasiglucagon returns 50 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Zegalogue
- Generic names
- DASIGLUCAGON
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA214231
Indications and usage. 1 INDICATIONS AND USAGE ZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. ZEGALOGUE is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Substantial Increase in Blood Pressure in Patients with Pheochromocytoma: Contraindicated in patients with pheochromocytoma because ZEGALOGUE may stimulate the release of catecholamines from the tumor. ( 4 , 5.1 ) • Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose, but ZEGALOGUE may stimulate exaggerate...
Contraindications. 4 CONTRAINDICATIONS ZEGALOGUE is contraindicated in patients with: • Pheochromocytoma because of the risk of substantial increase in blood pressure [see Warnings and Precautions (5.1) ] • Insulinoma because of the risk of hypoglycemia [see Warnings and Precautions (5.2) ] Pheochromocytoma ( 4 ) Insulinoma ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.